Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04434209 · ClinicalTrials.gov registry record · NA
A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)
A NA study, sponsored by BioMérieux.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT04434209 is a NA study that was terminated before completion, run by BioMérieux. The registered enrollment target is 19 participants.
The verdict
NCT04434209, a NA study, was terminated before completion, sponsored by BioMérieux.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
Biomarkers that provide an early indicator of kidney stress could be useful in clinical practice to detect silent episodes of acute kidney injury (AKI) or for early identification of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators of AKI. The NephroCheck® test is a commercially available test that uses these biomarkers, and this study assesses the use of these in reducing negative clinical outcomes for patients with sepsis-associated AKI. The study will enroll subjects diagnosed with sepsis, including septic shock, who will be randomly assigned to either receive NephroCheck®-guided kidney-sparing and fast-tracking interventions; or to receive current Standard of Care assessment and treatment. NOTE: Participants are no longer being recruited to this study.
Interventions
- OTHER Standard of Care
- DEVICE Subject management guided by NephroCheck® test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2022-02-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04434209
The ClinicalTrials.gov registry entry for NCT04434209 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMérieux, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04434209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04434209 about?
NCT04434209 is a clinical study titled "A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)". Biomarkers that provide an early indicator of kidney stress could be useful in clinical practice to detect silent episodes of acute kidney injury (AKI) or for early identification of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators of AKI. The NephroCheck® tes...
What is the current status of trial NCT04434209?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2021-01-19. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT04434209?
The interventions under investigation include: Standard of Care (OTHER), Subject management guided by NephroCheck® test (DEVICE).
Who is sponsoring clinical trial NCT04434209?
This trial is sponsored by BioMérieux, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.